MedTrace Logo

A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.

NCT06085924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8252912

Last updated 2025-11-25

No results posted yet for this study

Summary

The purpose of this study is to learn about:

* effects of living with COVID-19 and
* how effective is nirmatrelvir-ritonavir in treating COVID-19.

This is a study of two groups of COVID-19 patients in Taiwan.

In Group 1 the below participants were included in the study:

* Patients of all ages.
* Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021.
* Cases of patients registered in the databases.

In Group 2 the below participants were included in the study:

* Participants who are 12 years or older.
* Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022.

Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19.

The study will look at:

* the nature of Covid-19 disease.
* as well as the experiences of people receiving the nirmatrelvir-ritonavir.

This study will help to:

* understand what type of patients will need to be admitted to hospitals.
* see severe results due to COVID 19 infection.
* have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.

Conditions

Interventions

DRUG

SoC

COVID-19 treatment as per government guidance

OTHER

Disease description

No intervention

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2025-02-28
Completion
2025-02-28
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06085924 on ClinicalTrials.gov